Navigation Links
Enobia Reports Positive Results For Phase II Trial of ENB-0040 in Juvenile Hypophosphatasia
Date:9/24/2010

PRAGUE, Sept. 24 /PRNewswire/ -- Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP).  Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages. Michael Whyte, MD, Medical/Scientific Director of the Center for Metabolic Bone Disease and Molecular Research at Shriners Hospital for Children in St. Louis, Missouri, and a principal investigator of the Phase II study, presented the findings at the European Society for Paediatric Endocrinology (ESPE) Annual Meeting in Prague. Enobia's abstract describing these Phase II results was awarded the Henning Anderson Prize for best clinical abstract by ESPE.

In this trial, after six months of ENB-0040 treatment results include:

  • Radiographic improvement of rickets
  • Improvement in muscle strength and agility over baseline, including an average improvement of 125m on six-minute walk test
  • Amelioration of pain in 6 of 7 patients experiencing pain at baseline  

"We are encouraged by these preliminary results. Improvements were seen in objective measures of muscle strength, agility and pain. These were accompanied by histomorphometric, radiologic and biomarker improvements, suggesting an integrated improvement of this debilitating skeletal disorder," said Hal Landy, MD, Chief Medical Officer at Enobia. "With nearly 50 patients on ENB-0040 treatment, we are rapidly expanding our understanding of the potential safety and efficacy of ENB-0040."  

Dr. Michael Whyte, Medical/Scientific Director of the Center for Metabolic Bone Disease and Molecular Research at Shriners Hospital for Children in St. Louis and a Principal Investigators said, "The findings from this study represent an important advance in o
'/>"/>

SOURCE Enobia Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
2. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
3. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
4. Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
5. Enobia Announces Positive Clinical Results With ENB-0040, a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... --  BioNano Genomics announced today achievement of a major ... data at 30X depth, sufficient for a genome map, in ... established and demonstrated for the IrysChip TM V2, the ... and will be rolled out to BioNano,s collaborators and customers ... advancement at the American Society for Human Genetics (ASHG) ...
(Date:10/20/2014)... 2014 Lpath, Inc. (NASDAQ: ... therapeutics, received official notification from the European Patent Office ... patent supporting its iSONEP™ and ASONEP™ programs. ... No. 2087002, claims compositions of matter related to ... compounds, iSONEP and ASONEP. Sonepcizumab is an antibody ...
(Date:10/20/2014)... 2014 Norgine B.V. today announced ... volume bowel preparation, NER1006, presented at the 79 th ... Gastroenterology (ACG), Philadelphia, PA , has ... and co-primary endpoint of cleansing success. The study demonstrated ... ® in screening colonoscopy patients. [1] ...
Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2
... 13, 2011 BD (Becton, Dickinson and Company) (NYSE: ... a subsidiary of Waste Management, Inc. (NYSE: ... sharps waste from hospitals and other healthcare facilities.  The ... Solution, an innovative service that will recycle medical sharps ...
... Healthcare Financial Management Association (HFMA) has recognized the ... ("SIS") as once again consistently meeting the "Peer ... offerings as part of the annual evaluation process ... HFMA Peer Reviewed designation.  ...
Cached Medicine Technology:BD and Waste Management Launch Initiative to Recycle Medical Sharps 2BD and Waste Management Launch Initiative to Recycle Medical Sharps 3BD and Waste Management Launch Initiative to Recycle Medical Sharps 4Surgical Information Systems Renews HFMA Peer Review Designation for Fourth Consecutive Year 2Surgical Information Systems Renews HFMA Peer Review Designation for Fourth Consecutive Year 3
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... 2014 National Teen Driver Safety Week is ... Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining ... of teen drivers to talk to their teens and always ... vehicle crashes are the leading cause of death for U.S. ... fatal crashes, and 859 (42%) of those teen drivers were ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... New York (PRWEB) October 19, 2014 ... Nations Population Fund, welcomes news of a ceasefire agreement ... the more than 200 girls who were kidnapped from ... girls have languished in captivity long enough, and it ... schools and communities," stated Dr. Osotimehin. , "We owe ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 SweetDressy.com, a ... recently announced its promotion for long evening dresses ... enjoy the special offer; the current discount is up ... of the industry pioneers in the fashion field. Its ... for ladies dwelling in various parts of the world. ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... Problems With Governor,s Mandatory Health Insurance Plan, ... today by the Schwarzenegger Administration fail to,protect patients ... decide which policies to cancel without prior review ... Consumer Rights (FTCR).,FTCR said that the weak cancellation ...
... Inc., an investment,company with a series of 20 ... by Standard & Poor,s, the calculating agent for ... trading on,Friday, October 26, 2007, Immunogen, Inc. (Nasdaq: ... BIVN ) in the HealthShares(TM) Emerging Cancer,Index. Bioenvision, ...
... Offers Tips for People with Diabetes Affected ... by California Wildfires, ... the following tips for people with diabetes who,are affected by the ... with diabetes,require additional supplies to manage their health. 1) Medication ...
... on November 13, 2007 at 8:00 am ... 9:00 pm (Beijing/Hong Kong), SHANGHAI, China, Oct. 23 ... ("WuXi PharmaTech" or "the Company"), the leading,China-based pharmaceutical and ... will release unaudited,financial results for the third quarter ended ...
... PDT (8:00 p.m. EDT), SUNNYVALE, Calif., Oct. 23 ... field of radiosurgery,announced today that it will host an investor ... the American Society of,Therapeutic Radiology and Oncology (ASTRO) in Los ... PDT. A live webcast of the presentation will begin ...
... -- Mayo Clinic today reported promising interim results from ... for patients with recurrent ovarian cancer that is resistant ... either complete or partial tumor regression from the therapy, ... this Phase 2 Consortium (P2C) clinical trial were presented ...
Cached Medicine News:Health News:Draft Rules Won't Stop Insurers' Illegal Cancellations of Health Policies 2Health News:Draft Rules Won't Stop Insurers' Illegal Cancellations of Health Policies 3Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Emerging Cancer Index 2Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Emerging Cancer Index 3Health News:Emergency Preparedness for People With Diabetes 2Health News:WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007 2Health News:WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007 3Health News:Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2007 2Health News:Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2007 3Health News:Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer 2
... For the quantitative determination of ... ,Patients with atopic allergic diseases such ... fever have been shown to exhibit ... blood. IgE is also known as ...
...
...
...
Medicine Products: